Physicians' Academy for Cardiovascular Education

LDL-c goal attainment in high risk patients

The series 'Experts in dialogue - LDL-c goal attainment in high risk patients' has been developed in response to an Expert Meeting, in which the current situation on LDL-c guideline implementation, barriers of implementation and solutions to improve the proportion of patients achieving their target goals were discussed.

A novel simplified algorithm to achieve LDL-c goal in very-high risk patients

15' education - May 11, 2021 - Prof. Luis Masana, MD, PhD and prof. Erik Stroes, MD, PhD
The approach of upfront combination therapy in very-high risk patients is easier for physicians and a big win for patients, according to prof. Stroes and prof. Masana.

Experts in dialogue The approach of upfront combination therapy in very-high risk patients is easier for physicians and a big win for patients, according to prof. Stroes and prof. Masana.

Lipid-lowering therapies for statin-intolerant patients

15' education - May 5, 2021 - Prof. Maciej Banach, MD, PhD and prof. Ulrich Laufs, MD, PhD

Experts in dialogue In a video on management of statin-intolerant patients, the discussants state that we are are in a good position in 2021 with new options of lipid-lowering therapies for these patients.

LDL-c goal attainment in high risk patients

EBAC-accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

This e-learning consists of three expert discussions in which the current situation on LDL-c guidelines implementation, barriers of LDL-c goal attainment and solutions to improve the proportion of patients achieving their target goals are discussed.

Solutions for improving LDL-c goal attainment - changing treatment patterns

15' education - Apr. 28, 2021 - Prof. Ulrich Laufs, MD, PhD and Derek Connolly, MD, PhD - Online CME
In this video, the discussant suggest to treat hypercholesterolemia with a similar treatment regimen as for hypertension, that is with combination therapy. They state that combination therapy for lipid lowering is the way to go.

Experts in dialogue In this video, the discussants suggest to treat hypercholesterolemia in very-high CV risk patients with a similar treatment regimen as for hypertension, that is with upfront combination therapy.

Solutions for improving LDL-c goal attainment - advances in patient selection

15' education - Apr. 20, 2021 - Prof. Maciej Banach, MD, PhD, and prof. John Kastelein, MD, PhD
For which patients should combination therapy with statin and ezetimibe directly be initiated and for whom triple therapy with PCSK9 targeted therapy or bempedoic acid?

Experts in dialogue For which patients should combination therapy with statin and ezetimibe directly be initiated and for whom triple therapy with PCSK9 targeted therapy or bempedoic acid?

What are current challenges and barriers in achieving LDL-c goals?

15' education - Apr. 13, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD - Online CME
Two lipid experts discuss what the possible barriers are for implementing guidelines and not reaching goals with regard to LDL-c and how to overcome these.

Experts in dialogue Two lipid experts discuss what the possible barriers are for implementing guidelines and not reaching goals with regard to LDL-c and how to overcome these barriers.

The gap between guideline LDL-c goals and current practice: how are we doing?

15' education - Apr. 1, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD - Online CME
In this video, prof. Mach and prof. Stroes answer the question: How are we performing in Europe with regard to LDL-c goal attainment in very high risk patients?

Experts in dialogue In this video, prof. Mach and prof. Stroes answer the question: How are we performing in Europe with regard to LDL-c goal attainment in very high risk patients?

The proven case for LDL-c lowering

15' education - Mar. 26, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD
Is the case for LDL-c lowering sufficiently proven or is there a need for more studies? Prof. Ray and Kastelein talk about this topic in depth and exchange views.

Experts in dialogue Is the case for LDL-c lowering sufficiently proven or is there a need for more studies? Prof. Ray and prof. Kastelein talk about this topic and exchange their views on LDL-c lowering.

LDL-c goal attainment in high risk patients